Wuxi Biologics Gains New Bull on Growing Order Backlog, Strong Momentum -- Market Talk

Dow Jones

2025/08/21

0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

August 21, 2025 05:41 ET (09:41 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2561463251"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561463251\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561463251?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-21 17:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561463251","market":"other","top_or_hot":-1,"title":"Wuxi Biologics Gains New Bull on Growing Order Backlog, Strong Momentum -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 21, 2025 05:41 ET (09:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wuxi Biologics Gains New Bull on Growing Order Backlog, Strong Momentum -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuxi Biologics Gains New Bull on Growing Order Backlog, Strong Momentum -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-08-21 17:41</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 21, 2025 05:41 ET (09:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0516422952.EUR","symbol_name":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2561463251","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561463251","pubTimestamp":1755769260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","BK1589":"北水核心资产","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0823426308.USD":"法巴中国股票基金","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","BK1141":"生命科学工具和服务","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","BK1576":"医药外包概念","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","02269":"药明生物","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0051755006.USD":"摩根大通中国A (dist)","BK1610":"ETF&股票定投概念","LU1720050803.USD":"安联全方位中国股票基金","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC"},"translate_title":"药明生物积压订单增长势头强劲，获得新牛市——市场谈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":0.9},"content_text":"0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 21, 2025 05:41 ET (09:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}